A European multicentre PET study of fibrillar amyloid in Alzheimers diseaseReportar como inadecuado

A European multicentre PET study of fibrillar amyloid in Alzheimers disease - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

European Journal of Nuclear Medicine and Molecular Imaging

, Volume 40, Issue1, pp 104114

First Online: 08 September 2012Received: 12 June 2012Accepted: 17 August 2012DOI: 10.1007-s00259-012-2237-2

Cite this article as: Nordberg, A., Carter, S.F., Rinne, J. et al. Eur J Nucl Med Mol Imaging 2013 40: 104. doi:10.1007-s00259-012-2237-2


PurposeAmyloid PET tracers have been developed for in vivo detection of brain fibrillar amyloid deposition in Alzheimers disease AD. To serve as an early biomarker in AD the amyloid PET tracers need to be analysed in multicentre clinical studies.

MethodsIn this study 238 CPittsburgh compound-B PIB datasets from five different European centres were pooled. Of these 238 datasets, 18 were excluded, leaving CPIB datasets from 97 patients with clinically diagnosed AD mean age 698years, 72 patients with mild cognitive impairment MCI; mean age 67.58years and 51 healthy controls mean age 67.46years available for analysis. Of the MCI patients, 64 were longitudinally followed for 2815months. Most participants 175 out of 220 were also tested for apolipoprotein E ApoE genotype.

ResultsCPIB retention in the neocortical and subcortical brain regions was significantly higher in AD patients than in age-matched controls. Intermediate CPIB retention was observed in MCI patients, with a bimodal distribution 64% MCI PIB-positive and 36% MCI PIB-negative, which was significantly different the pattern in both the AD patients and controls. Higher CPIB retention was observed in MCI ApoE 4 carriers compared to non-ApoE 4 carriers p<0.005. Of the MCI PIB-positive patients, 67% had converted to AD at follow-up while none of the MCI PIB-negative patients converted.

ConclusionThis study demonstrated the robustness of CPIB PET as a marker of neocortical fibrillar amyloid deposition in brain when assessed in a multicentre setting. MCI PIB-positive patients showed more severe memory impairment than MCI PIB-negative patients and progressed to AD at an estimated rate of 25% per year. None of the MCI PIB-negative patients converted to AD, and thus PIB negativity had a 100% negative predictive value for progression to AD. This supports the notion that PIB-positive scans in MCI patients are an indicator of prodromal AD.

KeywordsAmyloidMulticentre PETPIBMCIAlzheimers diseaseMild cognitive impairmentCognitionElectronic supplementary materialThe online version of this article doi:10.1007-s00259-012-2237-2 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: AgnetaNordberg - StephenF.Carter - JuhaRinne - AlexanderDrzezga - DavidJ.Brooks - RikVandenberghe - DanielaPerani - AntonForsberg

Fuente: https://link.springer.com/

Documentos relacionados